Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis
Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a...
Main Authors: | Tamara Quint, Patrick M. Brunner, Christoph Sinz, Irene Steiner, Robin Ristl, Kornelia Vigl, Susanne Kimeswenger, Katharina Neubauer, Detlev Pirkhammer, Martin Zikeli, Wolfram Hoetzenecker, Norbert Reider, Christine Bangert |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/4/1241 |
Similar Items
-
Conjunctivitis in patients with atopic dermatitis treated with dupilumab
by: Sandra Ferreira, et al.
Published: (2020-05-01) -
Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
by: Gavin Li, et al.
Published: (2020-09-01) -
Cicatricial ectropion in a patient treated with dupilumab
by: Alexander C. Barnes, et al.
Published: (2017-09-01) -
Transient Increase in Circulating Basophils and Eosinophils in Dupilumab-associated Conjunctivitis in Patients with Atopic Dermatitis
by: Michie Katsuta, et al.
Published: (2021-06-01) -
MALLASEZIA FOLLICULITIS ON THE NECK
by: Brzeziński Piotr, et al.
Published: (2010-10-01)